Home › Compare › QFREF vs ABBV
QFREF yields 158.73% · ABBV yields 3.12%● Live data
📍 QFREF pulled ahead of the other in Year 1
Combined, QFREF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QFREF + ABBV for your $10,000?
Q-Free ASA supplies intelligent transportation system products and solutions worldwide. It offers tolling products, such as dedicated short-range communication on-board units, roadside transceivers/antennas, handheld transceivers/digital tachographs, and automated license plate recognition (ALPR) cameras/imaging systems. The company also provides Intrada ALPR, an automatic license plate recognition and vehicle analytics solution; Intrada Insight, an image processing and review solution; and Intrada Synergy Server, an image processing solution for video-based passages, such as tolling and parking/access control. In addition, it offers traffic management products, including Urban hardware, such as ATC controllers and cabinets; urban software comprising central and local traffic control software systems, as well as ramp meter, analytics, adaptive, and connected vehicle software enhancements; interurban software, such as Statewide ATMS, a statewide freeway traffic management software system, as well as software enhancements for work zone and event management; and infomobility hardware products, including high- and low-speed weigh-in-motion systems, as well as traffic counting and classification products for vehicles, bicycles, and pedestrians. The company also provides maintenance services. Q-Free ASA was founded in 1984 and is headquartered in Trondheim, Norway.
Full QFREF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.